Molecular Partners (MOLN) has released an update.
Molecular Partners, a clinical-stage biotech company, has announced significant advancements in its Radio-DARPin therapeutic programs, including preparations for clinical trials of its MP0712 candidate in 2025. The company has strengthened its partnership with Orano Med to co-develop four 212Pb-based candidates and raised approximately USD 20 million in a recent offering to support its R&D initiatives. With a robust cash position of CHF 158 million, Molecular Partners is well-funded into 2027, indicating strong financial health and growth potential.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.